NYSE:NSPR InspireMD (NSPR) Stock Price, News & Analysis $3.39 +0.41 (+13.76%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.96▼$3.4250-Day Range$2.28▼$3.3952-Week Range$1.81▼$3.85Volume100,953 shsAverage Volume26,636 shsMarket Capitalization$84.51 millionP/E RatioN/ADividend YieldN/APrice Target$4.85 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends Get InspireMD alerts: Email Address InspireMD MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside43.1% Upside$4.85 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.82) to ($0.69) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.37 out of 5 starsMedical Sector753rd out of 936 stocksSurgical & Medical Instruments Industry81st out of 101 stocks 3.5 Analyst's Opinion Consensus RatingInspireMD has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageInspireMD has received no research coverage in the past 90 days.Read more about InspireMD's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for NSPR. Previous Next 0.0 Dividend Strength Dividend YieldInspireMD does not currently pay a dividend.Dividend GrowthInspireMD does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NSPR. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for InspireMD this week, compared to 0 articles on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, InspireMD insiders have not sold or bought any company stock.Percentage Held by Insiders29.72% of the stock of InspireMD is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions44.78% of the stock of InspireMD is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about InspireMD's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for InspireMD are expected to grow in the coming year, from ($0.82) to ($0.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of InspireMD is -4.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of InspireMD is -4.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInspireMD has a P/B Ratio of 1.85. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about InspireMD's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agency5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here.Click here to pay just $5 for a full year of Stealth Trades About InspireMD Stock (NYSE:NSPR)InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.Read More NSPR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NSPR Stock News HeadlinesJuly 21, 2024 | americanbankingnews.comInspireMD (NYSE:NSPR) Earns Sell Rating from Analysts at StockNews.comMay 28, 2024 | globenewswire.comInspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024July 26, 2024 | WealthPress (Ad)This TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.May 15, 2024 | markets.businessinsider.comInspireMD earnings preview: what Wall Street is expectingMay 14, 2024 | investorplace.comNSPR Stock Earnings: InspireMD Misses EPS, Beats Revenue for Q1 2024May 14, 2024 | globenewswire.comInspireMD Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 7, 2024 | globenewswire.comInspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14thApril 26, 2024 | ca.finance.yahoo.comInspireMD, Inc. (NSPR)July 26, 2024 | WealthPress (Ad)This TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.April 3, 2024 | finance.yahoo.comInspireMD to Present at the 23rd Annual Needham Virtual Healthcare ConferenceApril 3, 2024 | globenewswire.comInspireMD to Present at the 23rd Annual Needham Virtual Healthcare ConferenceMarch 31, 2024 | msn.comPope Francis appeals for Gaza cease-fire and Russia-Ukraine prisoner swap in Easter Sunday prayersMarch 26, 2024 | globenewswire.comInspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024March 6, 2024 | finanznachrichten.deInspireMD, Inc.: InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateMarch 6, 2024 | investorplace.comNSPR Stock Earnings: InspireMD Beats EPS, Beats Revenue for Q4 2023March 6, 2024 | globenewswire.comInspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateMarch 5, 2024 | benzinga.comPreview: InspireMD's EarningsFebruary 28, 2024 | globenewswire.comInspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6thSee More Headlines Receive NSPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InspireMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNYSE:NSPR CUSIPN/A CIK1433607 Webwww.inspiremd.com Phone9728887766804FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Stock Price Target$4.85 High Stock Price Target$5.20 Low Stock Price Target$4.50 Potential Upside/Downside+43.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,920,000.00 Net Margins-350.35% Pretax Margin-349.34% Return on Equity-55.12% Return on Assets-46.95% Debt Debt-to-Equity RatioN/A Current Ratio7.90 Quick Ratio7.41 Sales & Book Value Annual Sales$6.20 million Price / Sales13.63 Cash FlowN/A Price / Cash FlowN/A Book Value$1.83 per share Price / Book1.85Miscellaneous Outstanding Shares24,930,000Free Float17,521,000Market Cap$84.51 million OptionableOptionable Beta0.96 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Marvin L. Slosman (Age 60)President, CEO & Director Comp: $843.83kMr. Craig Shore (Age 63)CFO, Chief Administrative Officer, Secretary & Treasurer Comp: $613.49kMr. Shane Thomas Gleason (Age 49)Chief Commercial Officer Comp: $486.04kMr. Andrea Tommasoli (Age 52)Chief Operating Officer Comp: $359.27kMr. Amir KohenVice President of Finance & Human ResourcesDr. Patrick A. Verta DVM (Age 66)M.D., MS Stat, Executive Vice President of Clinical & Medical Affairs Mr. Pete LigottiExecutive VP & GM of North AmericaDr. Sol J. Barer Ph.D. (Age 77)Special Advisor to the Board Comp: $13.92kMore ExecutivesKey CompetitorsNeuroPaceNASDAQ:NPCEDelcath SystemsNASDAQ:DCTHBeauty HealthNASDAQ:SKINCVRxNASDAQ:CVRXClearPoint NeuroNASDAQ:CLPTView All CompetitorsInsiders & InstitutionsRosalind Advisors Inc.Bought 1,827,579 shares on 7/12/2024Ownership: 10.083%Gary S RoubinBought 50,000 shares on 11/30/2023Total: $126,500.00 ($2.53/share)View All Insider TransactionsView All Institutional Transactions NSPR Stock Analysis - Frequently Asked Questions How have NSPR shares performed this year? InspireMD's stock was trading at $2.81 on January 1st, 2024. Since then, NSPR shares have increased by 20.6% and is now trading at $3.39. View the best growth stocks for 2024 here. How were InspireMD's earnings last quarter? InspireMD, Inc. (NYSE:NSPR) announced its quarterly earnings data on Tuesday, May, 14th. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by $0.06. The company earned $1.51 million during the quarter, compared to analyst estimates of $1.38 million. InspireMD had a negative trailing twelve-month return on equity of 55.12% and a negative net margin of 350.35%. Who are InspireMD's major shareholders? InspireMD's top institutional shareholders include Rosalind Advisors Inc. (10.08%). Insiders that own company stock include Gary S Roubin and Paul Stuka. View institutional ownership trends. How do I buy shares of InspireMD? Shares of NSPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of InspireMD own? Based on aggregate information from My MarketBeat watchlists, some other companies that InspireMD investors own include Akorn (AKRXQ), Akers Biosciences (AKER), Akebia Therapeutics (AKBA), Adamis Pharmaceuticals (ADMP), ADMA Biologics (ADMA), Acasti Pharma (ACST) and AcelRx Pharmaceuticals (ACRX). This page (NYSE:NSPR) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InspireMD, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share InspireMD With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.